Navigation Links
Medivir Announces TMC435 in an Expanded Clinical Collaboration
Date:4/18/2012

C435, a novel protease inhibitor in phase III clinical development for hepatitis C that is being developed in collaboration with Janssen Pharmaceuticals.

In June 2011, Medivir acquired the specialty pharmaceutical company BioPhausia to ensure timely commercialisation of TMC435 in the Nordic markets, once approved.

Medivir's first product, the unique cold sore product Xerese®/Xerclear®, was launched on the US market in 2011. Xerese®/Xerclear®, which has been approved in both the US and Europe, is being launched in collaboration with GlaxoSmithKline to be sold OTC in Europe, Japan and Russia. Rights in North America, Canada and Mexico were sold to Meda AB in June 2011. Medivir has retained the Rx rights for Xerclear® in Sweden and Finland.

For more information about Medivir, please visit the Company's website: http://www.medivir.com

For more information about Medivir, please contact:

Medivir
Rein Piir, EVP Corporate Affairs & IR    
Mobile: +46-708-537-292 

M:Communications
Europe: Mary-Jane Elliott, Amber Bielecka, Hollie Vile    
medivir@mcomgroup.com
+44(0)20-7920-2330



'/>"/>
SOURCE Medivir
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Medivir: R&D Day
2. Inspiration Biopharmaceuticals Announces Filing of Biologics License Application (BLA) for IB1001, a Recombinant Factor IX Product for People with Hemophilia B
3. CardioInsight Announces Appointment of Jim Bullock as Chairman of the Board of Directors
4. WaferGen Bio-systems Announces Open Format qPCR Platform and Strategic Realignment
5. Custom Spine Announces 510K Clearance for Securis Cannulated Screw System
6. BioRestorative Therapies Announces Closing of License Agreement for Adult Stem Cell Disc/Spine Procedure
7. Islet Sciences Announces Receipt of $2.1 Million in Grant Support of Technology
8. ADVENTRX Announces Establishment of Regulatory Advisory Board
9. Genesis Biopharma Announces Proposed Public Offering of Common Stock and Warrants
10. Syndax Pharmaceuticals Announces Start of Phase 1/2 Study of Entinostat in Combination with Lapatinib in HER2-Positive Metastatic Breast Cancer
11. GenVec Announces Research on Improved Vaccine Vectors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/18/2014)... NY (PRWEB) September 18, 2014 Whitehouse ... negotiations with Salem Realty Group and has acquired an ... space within the Salem Executive Complex adjacent to its ... was held on Friday September 5th. Whitehouse Labs is ... the entire space specifically for package testing. The prime ...
(Date:9/17/2014)... A long-term retrospective study of breast ... via interstitial brachytherapy suggests that women younger than ... be suitable to receive the treatment. Current American ... patients in the "unsuitable" category for APBI. In ... Beaumont Health System,s Peter Y. Chen , ...
(Date:9/17/2014)... SEATTLE, WA , Sept. 17, 2014 /PRNewswire/ - ... that it intends to offer and sell shares of ... in separate but concurrent underwritten public offerings.  The Series ... shares of Oncothyreon Common Stock, provided that conversion will ... its affiliates would beneficially own more than 4.99% of ...
(Date:9/17/2014)... DIEGO and PRINCETON, N.J. ... (NASDAQ: OTCQB:AEMD), the pioneer in developing targeted therapeutic devices ... and its diagnostic subsidiary, Exosome Sciences, Inc. (ESI), disclosed ... 2014 Exosomes & SingleCell Analysis Summit. On ... Exosome Sciences will give a presentation entitled: "Exosomes: A ...
Breaking Biology Technology:Whitehouse Labs Announces Package Testing Laboratory Expansion 2Whitehouse Labs Announces Package Testing Laboratory Expansion 3Whitehouse Labs Announces Package Testing Laboratory Expansion 4Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 2Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 3Partial Breast Irradiation With Interstitial Brachytherapy Appears Appropriate For Women Previously Considered Unsuitable 4Oncothyreon Announces Proposed Public Offerings 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 2Aethlon Medical and Exosome Sciences To Present at the Exosomes & SingleCell Analysis Summit 3
... /PRNewswire-FirstCall/ - Oncolytics Biotech Inc.,("Oncolytics") (TSX:ONC, NASDAQ:ONCY) ... to pursue a pivotal (Phase II/III) randomized ... in refractory,patients with head and neck cancers. ... results by the Company,s Board of Directors ...
... BOZEN, Italy, November 4 Health-Robotics today,announced ... strategic partnership with,Arabian Health Care Supply Corporation ... IV Solution provider within the Gulf,Cooperation Council ... cost-effectively automate the preparation of life-critical hazardous,and ...
... team up in specialty biologics development, TORONTO ... and,Therapure BioPharma Inc. have agreed to partner in ... for cancer treatments, with a goal of,advancing the ... a,marketing partner to add to its portfolio of ...
Cached Biology Technology:Oncolytics Biotech Inc. Announces Decision to Pursue Phase II/III Pivotal Clinical Trial 2Health Robotics Announces Contract for its CytoCare(TM) and IV Station(TM) Robots With Arabian Health Care Supply Corporation 2Health Robotics Announces Contract for its CytoCare(TM) and IV Station(TM) Robots With Arabian Health Care Supply Corporation 3Health Robotics Announces Contract for its CytoCare(TM) and IV Station(TM) Robots With Arabian Health Care Supply Corporation 4Therapure Biopharma Inc. announces collaboration with BioVectra Inc. 2
(Date:9/18/2014)... rabbitfish which have devastated algal forests in the eastern ... Mediterranean basin if their distribution continues to expand as ... by an international team of researchers led by Dr ... of the Mediterranean Institute for Advanced Studies in Spain, ... Members of the team surveyed more than 1000 kilometres ...
(Date:9/18/2014)... roaches of the fish world, are the ideal animal ... shape. They,ve moved from the ocean into tens of ... each time changing their skeleton to adapt to the ... populations of sticklebacks now have turned up one of ... a simple change in that gene,s regulation in a ...
(Date:9/17/2014)... accessible and affordable health care to reproductive technologies, ... on the ability of people to identify key ... and respectfully, and find the most defensible ways ... to support these societal conversations?, The Hastings Center ... Bioethical Issues have teamed up to publish a ...
Breaking Biology News(10 mins):Tropical fish a threat to Mediterranean Sea ecosystems 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3Why bioethics literacy matters 2Why bioethics literacy matters 3
... LAFAYETTE, Ind. - Researchers at Purdue University have ... holograms to precisely position numerous tiny particles within ... biological samples or create devices using nanoassembly. ... potential alternative to existing technologies because the patterns ...
... With their sedentary lifestyles and filter-feeding habits, clams have ... inflicted upon their waters. These clams are silent ... Dauphin Island Sea Lab and her colleagues have reported ... Aquatic Biology . Using stable isotope techniques, Carmichael ...
... New Haven, Conn.Organizations in the United States that are ... change are not adapting enough to the dangers posed ... "Despite a half century of climate change that has ... already had widespread ecological and hydrological impacts, and despite ...
Cached Biology News:New holographic method could be used for lab-on-a-chip technologies 2New holographic method could be used for lab-on-a-chip technologies 3New holographic method could be used for lab-on-a-chip technologies 4Most US organizations not adapting to climate change 2Most US organizations not adapting to climate change 3
... Mouse L1210 cells were cultured in DMEM and ... In order to keep the antigens in their ... The cells are arrayed on a 12-well (5 ... specifically treated to enhance cellular attachment and to ...
... P815 cells were cultured in DMEM and harvested ... order to keep the antigens in their native ... cells are arrayed on a 12-well (5 mm) ... treated to enhance cellular attachment and to minimize ...
...
Screening assay to detect the Listeria monocytogenes in food samples by,DNA amplification and molecular hybridization on a microtiter plate....
Biology Products: